Highest-materiality recent filing
Aspire Biopharma signs $30M cash deal for auto supplier DCS with >$200M revenue
DCS generated >$200M revenue, >$22M Adjusted EBITDA, >$17M net income in FY2025 (unaudited).
Aspire Biopharma files 1-for-30 reverse stock split
Filed 1-for-30 reverse stock split of common stock on May 11, 2026.
Aspire Biopharma closes $21M private placement, secures $22.5M credit facility for DCS acquisition
Closed second tranche of $10M (12,500 preferred shares); total gross proceeds $21M from private placement.
Purchase price of $30M cash for 100% of DCS; DCS generated >$200M revenue and >$22M adjusted EBITDA in FY2025 (unaudited).
Aspire Biopharma shareholders approve reverse stock split and authorized share increase
Reverse stock split ratio range 1:5 to 1:500 approved: 2,096,356 for, 582,185 against, 12,852 abstain.
Aspire Biopharma closes $10M second tranche of Series A preferred offering; amends certificate
Second closing issued 12,500 Series A Convertible Preferred Shares for gross proceeds of $10,000,000.
Aspire Biopharma signs LOI to acquire Driver Controls Systems unit for $30M
Entered non-binding LOI to acquire Driver Controls Systems business unit of Firefish Topco for $30M cash-free, debt-free.
Aspire Biopharma raises up to $21M via convertible preferred stock; board adds Balatsos
Initial closing of 13,750 Series A Convertible Preferred Shares for $11M gross proceeds; up to $21M total available.
Filed Certificate of Designation for 25,000 shares of Series A Convertible Preferred Stock on Feb 2, 2026.
Aspire Biopharma converts ~$1.75M debt from PowerUp sponsors into common stock
Exchanged ~$1.75M debt for common stock at closing price less $0.01/share; holders can submit up to 4 exchange notices by Jan 31, 2026.
Aspire Biopharma enters $100M ELOC with Arena, terminates prior ELOC
Entered into $100M equity line of credit (ELOC) with Arena Business Solutions, effective Nov 11, 2025.
Aspire Biopharma holders approve reverse split (1:5-1:40) and 19.99%+ note issuance
Reverse stock split proposal passed: 24,965,481 for, 5,988,513 against, 29,704 abstain.
Nasdaq notifies Aspire Biopharma of delisting for MVLS and bid price non-compliance; company appeals
On Oct 15, 2025, Nasdaq Staff notified the Company of delisting due to failure to comply with the MVLS Rule ($50M minimum) and Bid Price Rule ($1.00 minimum).
Aspire Biopharma dismisses auditor Bush, appoints Turner Stone; gets $1M funding tranche
Dismissed Bush & Associates CPA as independent auditor effective Sept 22, 2025; 2024 audit included going concern explanatory paragraph.
Aspire Biopharma raises $7.75M via convertible notes with 20% OID, maturity Feb 2026
Aggregate principal $9.6875M issued at $7.75M subscription price (20% OID) for three tranches.
CEO and two directors resign; interim CEO appointed; director cites irreconcilable differences
Michael Howe steps down as CEO and Director effective July 24, 2025; no disagreement with company.
Aspire Biopharma CEO Kraig Higginson Steps Down, Michael C. Howe Appointed as New CEO
Kraig Higginson resigned as CEO effective June 10, 2025, and will serve as Executive Chairman.
Aspire Biopharma settles lender default claims, extends note maturities by 75 days
Lenders withdrew April 1 and April 9 default/acceleration notices; defaults deemed cured with no admission of fault.
Aspire Biopharma receives Nasdaq delisting notices for MVLS below $50M and bid price under $1.00
Received two letters on April 16, 2025: MVLS deficiency (below $50M for 30 consecutive days) and bid price deficiency (below $1.00).
Aspire Biopharma closes SPAC merger with PowerUp; issues $3.75M convertible debentures
Business combination closed Feb 17, 2025: Aspire Biopharma becomes wholly owned sub of Aspire Biopharma Holdings (ASBP). Outstanding: 46M shares, 14.4M warrants.
Aspire Biopharma closes SPAC merger, lists on Nasdaq; enters $100M equity line
Completed business combination with PowerUp Acquisition Corp.; began trading on Nasdaq Feb 20 under ASBP/ASBPW.
PowerUp shareholders approve merger with Aspire Biopharma; redemptions of ~$5.8M
All proposals approved at Feb 4 meeting, including business combination, domestication, and charter changes.
PowerUp Acquisition Corp. amends Aspire Biopharma merger; consideration set at $350M
Merger consideration adjusted to $350M less cash shortfall and debt, reflecting anticipated ownership percentages.
PowerUp Acquisition announces definitive merger with Aspire Biopharma at $316M pre-money valuation
Pre-money equity value of Aspire approximately $316 million.
Consideration to Aspire stockholders: shares of New Aspire Common Stock valued at $316.8M less indebtedness and cash shortfall.
PowerUp Acquisition terminates merger with Visiox Pharmaceuticals on July 19
Terminated Merger Agreement with Visiox Pharmaceuticals due to failure to satisfy closing conditions by June 30, 2024.
PowerUp Acquisition amends merger with Visiox: Outside Date extended to June 30, 2024
Outside Date moved from May 31 to June 30, 2024; PowerUp's indebtedness cap increased to $2M.
Shareholders approved extending the deadline to consummate an initial business combination from May 23, 2024 to February 17, 2025.
Non-redemption agreement with unaffiliated shareholder for up to 450,000 Public Shares at the May 22, 2024 extraordinary general meeting to approve extension.
Extraordinary general meeting further postponed to 2:00 p.m. ET on May 22, 2024 to vote on extending business combination deadline to Feb. 17, 2025.
PowerUp Acquisition Corp. enters merger with Visiox Pharmaceuticals for $80M base consideration
Base merger consideration of $80M, subject to net working capital, transaction expenses, and indebtedness adjustments.
PowerUp Acquisition Corp. changes sponsor, board and officers; new CEO appointed
New sponsor SRIRAMA Associates acquired 4,317,500 Class A shares and 6,834,333 warrants for $1 total.
PowerUp Acquisition Corp. enters sponsor transfer agreement with SRIRAMA Associates for $1.00
Sponsor sells 4,317,500 Class A shares and 6,834,333 private warrants to SRIRAMA for $1.00, payable at business combination.
PowerUp Acquisition extends deadline to May 2024; ~$283M redeemed from trust
Shareholders approved extension of business combination deadline from May 23, 2023 to May 23, 2024.
the Board of Directors appointed Michael Howe, currently a member of the Board of Directors, to serve as Chief Executive Officer of the Company, effective June 10, 2025.
On June 10, 2025, Kraig Higginson, Chief Executive Officer of Aspire Biopharma Holdings, Inc. (the “Company”), notified the Board of Directors of his intention to step down from the role of Chief Executive Officer, effective June 10, 2025.
(i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”)
(iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”)
(ii) Jack Tretton, Michael Olson, and Gabriel Schillinger resigned as officers of the Company
(iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”)
(ii) Jack Tretton, Michael Olson, and Gabriel Schillinger resigned as officers of the Company
(i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”)
(i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”)
(iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”)
(ii) Jack Tretton, Michael Olson, and Gabriel Schillinger resigned as officers of the Company
(i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”)
Max materiality 0.90 · Median 0.68 · Most common event other_material